# Aflibercept

## Eylea aflibercept 2mg/0.05mL

| 藥物代碼           | IEYL                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|:-------------------|:----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 適應症             | Treatment of neovascular (wet) age-related macular degeneration (AMD).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| 副作用             | >10%: Ocular: Conjunctival hemorrhage (12% to 25%), eye pain (9% to 13%)1% to 10%:Local: Injection site pain (3%), injection site hemorrhage (1%)Ocular: Intraocular pressure increased (5% to 8%), cataract (7%), vitreous detachment (6%), vitreous floaters (5% to 6%), conjunctival hyperemia (4% to 5%), corneal erosion (4% to 5%), foreign body sensation (3%), lacrimation increased (3%), retinal pigment epithelium detachment (3%), blurred vision (1% to 2%), retinal pigment epithelium tear (2%), eyelid edema (1%), corneal edema (1%)Miscellaneous: Aflibercept antibodies (1% to 3%)<1% (Limited to important or life-threatening): Endophthalmitis, hypersensitivity, intraocular inflammation, retinal detachment, retinal tear, thromboembolic events, traumatic cataract |
| 禁忌               | 1.Ocular or periocular infection2.Active intraocular inflammation3.Hypersensitivity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| 藥物保存方式       | 2-8℃                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| 用法用量           | Age-related macular degeneration (AMD): Intravitreal injection: 2 mg (0.05 mL) every 4 weeks for 3 months then every 8 weeks thereafter Macular edema following central retinal vein occlusion (CRVO): Intravitreal injection: 2 mg (0.05 mL) every 4 weeks                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| 肝功能異常         | 無需調整劑量                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| 腎功能異常         | 無需調整劑量                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| 懷孕用藥危分級     | 除非治療上需要                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| 孕期用藥建議       | No (Limited) Human Data - animal data suggest low risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| 附帶說明           | AFLIBERCEPT OPHTHALMIC Vascular Endothelial Growth Factor Antagonist PREGNANCY RECOMMENDATION: No Human Data—Animal Data Suggest Low Risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| 哺乳期用藥建議     | No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| 附帶說明           | Micromedex Lactation Rating: Infant risk cannot be ruled out. Breastfeeding is not recommended in women who are receiving aflibercept as it is unknown whether aflibercept is excreted in human breast milk and the potential risk to the nursing infant cannot be excluded. After considering the importance of the drug to the mother, either nursing or treatment with aflibercept should be discontinued AFLIBERCEPT OPHTHALMIC Vascular Endothelial Growth Factor Antagonist BREASTFEEDING RECOMMENDATION: No Human Data—Probably Compatible                                                                                                                                                                                                                                             |
| 注射劑給藥建議途徑 | IVI                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| 乾粉稀釋液         | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| 輸注點滴液         | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| IVP 用法建議       | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| IVD 用法建議       | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| 注意事項           | 僅供眼科玻璃體內注射用。EYLEA 必須由合格醫師注射。                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |

